Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
FENC Stock Chart & Stats
$7.86
-$0.02(-0.33%)
At close: 4:00 PM EST
$7.86
-$0.02(-0.33%)
Day’s Range― - ―
52-Week Range$4.68 - $9.92
Previous Close$6.08
Volume58.66K
Average Volume (3M)173.43K
Market Cap
$271.68M
Enterprise Value$212.15M
Total Cash (Recent Filing)$21.93M
Total Debt (Recent Filing)$18.09M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Apr 01, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding34,139,973
10 Day Avg. Volume141,099
30 Day Avg. Volume173,430
Financial Highlights & Ratios
PEG Ratio3.19
Price to Book (P/B)-22.88
Price to Sales (P/S)2.83
P/FCF Ratio4.98
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue5.47
Enterprise Value/Gross Profit5.87
Enterprise Value/Ebitda-57.20
Forecast
1Y Price Target
$14.67Price Target Upside86.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Capital StructureElimination of all outstanding debt improves the company's financial flexibility and positions it to support commercialization and margin expansion.
Clinical Guideline InclusionInclusion of PEDMARK in national clinical guidelines for adolescents and young adults expands the addressable patient population beyond pediatrics, supporting potential revenue growth.
Regulatory Approval And ExclusivityPEDMARK's status as the only FDA-approved therapy to reduce cisplatin-related hearing loss supports pricing power and limits direct treatment competition.
Bears Say
Commercial Adoption RiskUncertain commercial adoption of PEDMARK could limit uptake and slow revenue momentum if clinicians or payers do not broadly adopt the therapy.
Concentration Of DemandSales relying heavily on adolescent and young adult uptake create concentration risk if expansion into additional patient segments proves more difficult than expected.
Intellectual Property VulnerabilityPotential challenges to intellectual property protection could expose PEDMARK to competition or lead to costly litigation that pressures long-term sales.
Fennec Pharmaceuticals News
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $4.68 and its highest was $9.92 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $271.68M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Apr 01, 2026 which is in 49 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Nov 13, 2025. The company reported -$0.021 earnings per share for the quarter, beating the consensus estimate of -$0.023 by $0.002.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.04.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,139,973 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -$0.021 in its last earnings report, beating expectations of -$0.023. Following the earnings report the stock price went up 2.211%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.67 (86.64% Upside)
$14.67 (86.64% Upside)
Blogger Sentiment
Bullish
FENC Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $9.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.39%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FENC Stock 12 Month Forecast
Average Price Target
$14.67
▲(86.64% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
NervGen Pharma
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―
Ownership Overview
9.69% Insiders
4.16% Mutual Funds
― Other Institutional Investors
80.58% Public Companies and
Individual Investors